Abstract
The vaccination roll-out of the COVID-19 vaccines in Israel has been highly successful. By February 9th, approximately 39% of the population has already been administered at least one dose of the BNT162b2 vaccine. Efforts to estimate the true real-world effectiveness of the vaccine have been hampered by disease dynamics and social-economic discrepancies. Here, using counts of positive and hospitalized cases of vaccinated individuals, we conduct a sensitive analysis of the vaccine effectiveness. Under an assumption of no effectiveness on the first two weeks after the 1st dose, the analysis shows effectiveness of 72% in reducing SARS-CoV-2 positive cases (symptomatic and asymptomatic), 83% reduction of COVID-19 hospitalizations and 86% reduction in severe cases in 60 years and older individuals the second week after the 2nd dose. On weeks 3-4 after the 2nd dose, we observe vaccine effectiveness of 95%+, however cases may still accumulate. Our analysis suggests that high effectiveness of the vaccine only starts after three weeks, which coincides with the administration of the 2nd dose. As more granular data will be available, it will be possible to extract more exact estimates; however, the emerging evidence suggest that the vaccine is highly effective in reducing cases, hospitalizations and deaths.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There was no specific funding for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB required for this work. All data is public.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Improved methodology and additional data to February 9th.
Data Availability
All data is public and can be downloaded from https://data.gov.il/dataset/covid-19 or Ministry of Health press releases. Data and code used in the analyses was deposited in https://github.com/dviraran/covid_analyses. In addition, a shiny app is available, which will be updated as more data is available by the Ministry of Health - https://dviraran.shinyapps.io/VaccineEffectIsrael/.
https://github.com/dviraran/covid_analyses
